| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 425 |
| 12 Nov 2026 |
8-K: Other Events
Rallybio Corporation (the “Company”) announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions contemplated by the Agreement and Plan of Merger and Reorganization (... |
| 10 Nov 2026 | 425 |
| 10 Nov 2026 |
8-K: Other Events
EAST BERLIN, Conn., November 10, 2026 – Rallybio Corporation (Nasdaq: RLYB) today announced that it will effect a one-for-two reverse stock split of its issued and outstanding common stock in connection with the transactions contemplated... |
| 06 Nov 2026 | 425 |
| 06 Nov 2026 |
8-K: Other Events
Rallybio Corporation (the “Company”) previously disclosed that, subject to the satisfaction or waiver of any outstanding closing conditions, the Company anticipated the transactions contemplated by the Agreement and Plan of Merger and Re... |
| 05 Nov 2026 |
Form 4: Mackay Martin, Director
Received 33,224 shares by exercise or conversion ($177K) |
| 05 Nov 2026 |
Form 4: Hunt Ronald, Director
Received 14,305 shares by exercise or conversion ($63.7K) |
| 04 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 03 Nov 2026 |
Form 4: Lieber Jonathan I, Chief Financial Officer
Received 7,124 shares by exercise or conversion ($106K) |
| 02 Nov 2026 |
Form 4: Lieber Jonathan I, Chief Financial Officer
Received 21,464 shares by exercise or conversion ($200K) |
| 02 Nov 2026 |
Form 4: Hunt Ronald, Director
Received 14,820 shares by exercise or conversion ($110K) |
| 30 Oct 2026 |
Form 4: Nash Christine A, Director
Received 3,562 shares by exercise or conversion ($8.48K) |
| 29 Oct 2026 |
Form 4: Uden Stephen, Director
Received 33,244 shares by exercise or conversion ($202K) |
| 28 Oct 2026 |
Form 4: Lieber Jonathan I, Chief Financial Officer
Received 2,500 shares as a grant or award · Sold 599 shares ($9.61K) |
| 28 Oct 2026 |
Form 4: Chung Wendy, Director
Received 2,062 shares by exercise or conversion ($31.5K) |
| 27 Oct 2026 | 10-Q |
| 26 Oct 2026 | 425 |
| 26 Oct 2026 |
8-K: Other Events
As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Avenzo Therapeutics, Inc., a Delawa... |
| 20 Oct 2026 |
Form 4: Soteropoulos Paula, Director
Received 3,562 shares by exercise or conversion ($8.48K) |
Loading...